Stay updated on Pembrolizumab Plus Lenvatinib Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Lenvatinib Clinical Trial page.

Latest updates to the Pembrolizumab Plus Lenvatinib Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov page continues to show a 403 error, and its footer revision marker changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content. This indicates access to the study details is blocked, with the usual navigation and study information not shown.SummaryDifference20%

- Check55 days agoChange DetectedThe page footer now shows Revision: v3.6.6, replacing the previous v3.6.5. This reflects a small version update to the page.SummaryDifference0.0%

- Check62 days agoChange DetectedA new line '2018 ( U.S. NIH Grant/Contract )' was added to the list of Other Study ID Numbers, signifying NIH funding/identifier associated with the LEAP-005 study.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page revision label was updated from v3.6.4 to v3.6.5, indicating a small patch to the page's tooling. No substantive study content or user-facing information appears to have changed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Plus Lenvatinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Lenvatinib Clinical Trial page.